GMILogo_Vertical-Gradient.png
Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc.
02 oct. 2024 05h42 HE | Global Market Insights Inc.
Selbyville, Delaware, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tumor Necrosis Factor Inhibitor Drugs Market size valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from...
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
24 sept. 2024 04h00 HE | AKAMPION
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has...
22157.jpg
Inflammatory Bowel Disease Digital Marketing Trends Report 2024: Highest Proportion of Traffic to Top Branded Patient IBD Websites Originated from Paid Sources, Followed by Organic Sources
06 sept. 2024 06h01 HE | Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Digital Marketing Trends in Inflammatory Bowel Disease - April 2024" report has been added to ResearchAndMarkets.com's offering. This report...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
16 juil. 2024 08h05 HE | Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
SciRhom Leadership Team
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
09 juil. 2024 02h00 HE | SciRhom GmbH
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary...
sphericalinsightsoptionblue.png
Global Fecal Calprotectin Test Market Size To Exceed USD 366.15 Million By 2033 | CAGR of 11.24%
22 juin 2024 02h00 HE | SPHERICAL INSIGHTS LLP
New York, United States , June 22, 2024 (GLOBE NEWSWIRE) -- The Global Fecal Calprotectin Test Market Size is to Grow from USD 126.15 Million in 2023 to USD 366.15 Million by 2033, at a CAGR of...
Organovo Logo (2 Color Med-Res-082117).png
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
21 mai 2024 08h05 HE | Organovo, Inc.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Organovo Logo (2 Color Med-Res-082117).png
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
14 mai 2024 11h00 HE | Organovo, Inc.
Organovo will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024
Organovo Logo (2 Color Med-Res-082117).png
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
08 mai 2024 20h00 HE | Organovo, Inc.
ONVO announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof).
Logo.png
Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena Pharmaceuticals, Pfizer, Abivax, Janssen, Celgene, Eli Lilly and Company, Merck Sharp & Dohme LLC, T
02 mai 2024 13h00 HE | DelveInsight Business Research LLP
New York, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Inflammatory Bowel Disease Market To Exhibit Significant Growth by 2032, Predicts DelveInsight | Key Companies Developing Therapies - Arena...